Equities research analysts forecast that Aptose Biosciences Inc (NASDAQ:APTO) (TSE:APS) will report ($0.13) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Aptose Biosciences’ earnings. The highest EPS estimate is ($0.10) and the lowest is ($0.15). Aptose Biosciences posted earnings per share of ($0.19) during the same quarter last year, which would suggest a positive year-over-year growth rate of 31.6%. The business is expected to announce its next earnings report after the market closes on Tuesday, March 27th.
According to Zacks, analysts expect that Aptose Biosciences will report full-year earnings of ($0.60) per share for the current year, with EPS estimates ranging from ($0.67) to ($0.53). For the next year, analysts expect that the company will post earnings of ($0.54) per share, with EPS estimates ranging from ($0.61) to ($0.47). Zacks Investment Research’s EPS averages are an average based on a survey of research firms that that provide coverage for Aptose Biosciences.
Several research analysts have commented on the company. HC Wainwright set a $4.00 price objective on Aptose Biosciences and gave the company a “buy” rating in a research report on Wednesday, November 15th. Zacks Investment Research raised Aptose Biosciences from a “sell” rating to a “hold” rating in a research report on Monday, December 25th. ValuEngine lowered Aptose Biosciences from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. Finally, Canaccord Genuity set a $7.00 price objective on Aptose Biosciences and gave the company a “buy” rating in a research report on Wednesday, November 15th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $5.00.
Aptose Biosciences (NASDAQ:APTO) traded up $0.24 during trading hours on Wednesday, reaching $3.52. The company’s stock had a trading volume of 621,255 shares, compared to its average volume of 456,660. Aptose Biosciences has a one year low of $0.78 and a one year high of $3.90. The stock has a market capitalization of $86.50, a price-to-earnings ratio of -5.91 and a beta of 2.50.
Aptose Biosciences Company Profile
Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.